310 related articles for article (PubMed ID: 33579785)
21. [Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].
Sato A; Hamada K; Imataka H
Gan To Kagaku Ryoho; 2012 May; 39(5):708-12. PubMed ID: 22584320
[TBL] [Abstract][Full Text] [Related]
22. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
[TBL] [Abstract][Full Text] [Related]
23. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
24. Translational insights into gastrointestinal stromal tumor and current clinical advances.
Hemming ML; Heinrich MC; Bauer S; George S
Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284
[TBL] [Abstract][Full Text] [Related]
25. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
Yonkus JA; Alva-Ruiz R; Grotz TE
Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
[TBL] [Abstract][Full Text] [Related]
26. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
[TBL] [Abstract][Full Text] [Related]
27. New targets and therapies for gastrointestinal stromal tumors.
Wozniak A; Gebreyohannes YK; Debiec-Rychter M; Schöffski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1117-1129. PubMed ID: 29110548
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal stromal tumours.
Blay JY; Kang YK; Nishida T; von Mehren M
Nat Rev Dis Primers; 2021 Mar; 7(1):22. PubMed ID: 33737510
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
30. Anagrelide for Gastrointestinal Stromal Tumor.
Pulkka OP; Gebreyohannes YK; Wozniak A; Mpindi JP; Tynninen O; Icay K; Cervera A; Keskitalo S; Murumägi A; Kulesskiy E; Laaksonen M; Wennerberg K; Varjosalo M; Laakkonen P; Lehtonen R; Hautaniemi S; Kallioniemi O; Schöffski P; Sihto H; Joensuu H
Clin Cancer Res; 2019 Mar; 25(5):1676-1687. PubMed ID: 30530703
[TBL] [Abstract][Full Text] [Related]
31. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
33. Durable tumor regression in highly refractory metastatic
Schroeder BA; Kohli K; O'Malley RB; Kim TS; Jones RL; Pierce RH; Pollack SM
Oncoimmunology; 2020; 9(1):1710064. PubMed ID: 32002307
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
Vadakara J; von Mehren M
Hematol Oncol Clin North Am; 2013 Oct; 27(5):905-20. PubMed ID: 24093167
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
[TBL] [Abstract][Full Text] [Related]
36. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
38. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Gounder MM; Maki RG
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
[TBL] [Abstract][Full Text] [Related]
40. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
